Asia-Pacific Point-Of-Care-Testing (POCT) Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Asia-Pacific Point-Of-Care-Testing (POCT) Market Size

• The Asia-Pacific Point-Of-Care-Testing (POCT) Market size was valued at USD 13.46 billion in 2025 and is expected to reach USD 31.99 billion by 2033, at a CAGR of 11.5% during the forecast period
• The growth of the Asia-Pacific Point-Of-Care-Testing (POCT) Market is primarily driven by the increasing demand for rapid diagnostic solutions that enable immediate clinical decision-making and reduce dependency on centralized laboratory testing. POCT devices allow faster turnaround times, early disease detection, and improved patient outcomes, which are critical in emergency care, remote healthcare, and home-based monitoring.
• The rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, infectious diseases, and respiratory illnesses is significantly increasing the adoption of POCT devices for real-time monitoring and management. Additionally, advancements in diagnostic technologies, microfluidics, biosensors, and connected healthcare platforms are enhancing accuracy, portability, and data integration capabilities, fueling market growth.

Asia-Pacific Point-Of-Care-Testing (POCT) Market Analysis

• The Asia-Pacific Point-Of-Care-Testing (POCT) Market is a rapidly expanding segment of the diagnostic industry, offering immediate test results directly at patient locations such as clinics, hospitals, ambulances, and home settings. POCT devices provide rapid screening and monitoring for conditions including diabetes, infectious diseases, pregnancy, cardiac markers, electrolyte imbalance, and coagulation parameters, enabling enhanced clinical efficiency and reduced healthcare system burden.
• The growing demand for portable and user-friendly diagnostic technologies is largely driven by rising chronic disease prevalence, emergency care needs, and the expansion of home-based patient monitoring. Additionally, the integration of digital health platforms, smartphone-based diagnostics, AI-enabled detection, and wireless connectivity supports improved data traceability and remote patient management, further advancing market growth.
• China is expected to dominate the Asia-Pacific Point-Of-Care-Testing (POCT) Market with the largest revenue share of around 26.23% in 2026, driven by the strong presence of key market players, high healthcare expenditure, advanced medical infrastructure, and rising adoption of innovative diagnostic technologies across hospitals and home-care environments.
• The Glucose Monitoring Products segment is expected to dominate the Asia-Pacific POCT market with a major share of over 40.96% in 2026, driven by the rising diabetic population, preference for real-time monitoring devices, and the growing use of portable blood glucose meters and continuous glucose monitoring tools among home-care patients.

Report Scope and Asia-Pacific Point-Of-Care-Testing (POCT) Market Segmentation 

Asia-Pacific Point-Of-Care-Testing (POCT) Market Trends

“Technological Advancements and Functional Expansion Through R&D and Digital Integration”

• A major and rapidly progressing trend in the Asia-Pacific Point-Of-Care-Testing (POCT) Market is the increasing focus on innovation, R&D, and advanced diagnostic technologies aimed at improving accuracy, speed, portability, and real-time decision-making. With rising demand for decentralized and patient-centric testing, healthcare providers, diagnostics companies, and medical device manufacturers are heavily investing in next-generation POCT platforms that support precision diagnostics and enhanced connectivity across care settings.
• Leading players such as Abbott, Roche, Siemens Healthineers, Danaher, and Thermo Fisher Scientific are accelerating research efforts to develop miniaturized devices, lab-on-chip technologies, and AI-enabled testing systems capable of delivering laboratory-quality results at the point of need. These technological advancements also include automated sample handling, improved biosensor sensitivity, and multiplex testing capabilities, enabling detection of multiple biomarkers simultaneously.
• In infectious disease diagnostics, extensive R&D initiatives are focused on producing rapid molecular testing solutions with high accuracy, shorter turnaround time, and suitability for emergency and outbreak situations. POCT devices designed for influenza, COVID-19, respiratory infections, HIV, and sepsis are being enhanced with microfluidics and isothermal amplification technologies, enabling reliable testing outside centralized labs.
• In chronic disease management, innovation in glucose monitoring, cardiac biomarker testing, coagulation tests, and renal function analysis is supporting continuous monitoring and providing real-time data for clinical intervention. Companies are integrating mobile applications, cloud-based reporting, and wearable diagnostics to enable seamless home monitoring and remote telehealth connectivity.
• The market is also witnessing expansion in personalized diagnostics, with POCT solutions being developed to support oncology, fertility, gastrointestinal disorders, and metabolic disease screening. These innovations aim to enable earlier detection, faster therapeutic decisions, and improved clinical outcomes, especially in outpatient and home-care settings.
• Furthermore, the integration of connected devices, digital data analytics, and AI-driven interpretation is enabling smarter POCT ecosystems that enhance workflow automation and reduce human error. These advancements are transforming POCT into a multifunctional and intelligent diagnostic tool capable of supporting preventive care, precision medicine, and population health management.
• This rapidly evolving, innovation-led environment is reshaping the POCT market, shifting the industry toward portable, integrated, and patient-centered diagnostic systems. As Asia-Pacific healthcare systems prioritize efficiency, accessibility, and sustainability, R&D-driven digital transformation is expected to unlock new applications and expand market penetration across both developed and emerging regions.

Asia-Pacific Point-Of-Care-Testing (POCT) Market Dynamics

Driver

“Growing Demand for Rapid, Decentralized, and Patient-Centric Diagnostic Solutions”

• A significant driver accelerating the growth of the Asia-Pacific Point-Of-Care-Testing (POCT) Market is the increasing need for fast, accessible, and decentralized diagnostic tools that improve clinical decision-making and patient outcomes. As healthcare systems shift toward value-based and patient-centered models, POCT offers immediate test results at or near the site of care, reducing dependence on centralized laboratories and enabling early diagnosis and timely treatment interventions.
• Leading industry players such as Abbott, Roche, Siemens Healthineers, and Danaher are actively expanding R&D investments to develop portable, highly accurate, and digitally connected POCT devices capable of supporting real-time diagnostics across hospitals, clinics, emergency settings, and home-care environments. These innovations align with the rising demand for integrated digital health solutions, telemedicine expansion, and AI-assisted result interpretation.
• In chronic disease management, POCT devices for glucose monitoring, cardiac biomarkers, coagulation testing, and renal assessment are experiencing rapid growth due to increasing Asia-Pacific prevalence of diabetes, cardiovascular diseases, and lifestyle disorders. Similarly, infectious disease POCT systems for COVID-19, influenza, sepsis, malaria, and HIV are becoming critical tools for outbreak control, especially in resource-limited regions.
• The growing focus on home-based and remote patient monitoring is also driving adoption, supported by the development of smartphone-enabled diagnostics, wearable testing solutions, cloud-based platforms, and remote reporting capabilities that enhance clinical connectivity and continuity of care.
• With healthcare infrastructure modernization, rising emphasis on rapid diagnostic turnaround, and strong public and private investments, POCT is emerging as an essential component for future healthcare delivery. As efficiency and accessibility become central to Asia-Pacific healthcare reform, the demand for innovative, accurate, and patient-driven POCT systems is expected to accelerate significantly.

Restraint/Challenge

“High Costs, Regulatory Complexities, and Accuracy & Standardization Concerns”

• Despite strong market growth, the Asia-Pacific Point-Of-Care-Testing (POCT) Market faces notable challenges related to high equipment and testing costs, stringent regulatory approval pathways, and variability in diagnostic accuracy across different device platforms. Ensuring consistent analytical performance comparable to centralized laboratory standards remains a key barrier, particularly as POCT expands into critical care and high-complexity testing segments.
• Obtaining approvals from regulatory bodies such as the FDA, EMA, and other national authorities requires extensive clinical validation, quality compliance, and post-market surveillance. These processes can significantly slow product launch timelines and increase development expenses for manufacturers, especially in emerging diagnostic technologies like molecular POCT and multiplex testing.
• Cost constraints also limit adoption in developing regions, where limited healthcare budgets and inadequate reimbursement systems restrict widespread deployment. Additionally, operational challenges such as maintenance requirements, user training needs, and workflow integration can hinder large-scale implementation across hospitals and diagnostic centers.
• Concerns regarding result accuracy, reliability, and standardization—particularly in high-sensitivity tests for infectious diseases and cardiac markers—can create hesitation among clinicians and increase reliance on centralized confirmatory testing. Issues related to data integration and cybersecurity in digital POCT platforms also demand enhanced technology frameworks and investment.
• As POCT technology evolves, overcoming these financial, regulatory, and technical challenges will require extensive R&D funding, improved Asia-Pacific harmonization of diagnostic standards, and strategic collaboration between device manufacturers, healthcare providers, and government health agencies. Until then, these barriers may continue to limit the pace of adoption in certain market segments and regions.

Asia-Pacific Point-Of-Care-Testing (POCT) Market Scope

The market is segmented on the basis of Product Type, Platform, Application, Prescription Mode, End User and Distribution Channel.

• By Product Type

On the basis of Product Type, the Asia-Pacific Point-Of-Care-Testing (POCT) Market is segmented into Glucose Monitoring Products, Infectious Disease Testing Products, Cardiometabolic Monitoring Products, Pregnancy and Fertility Testing Products, Hematology Testing Products, Coagulation Monitoring Products, Drugs-Of-Abuse (DOA) Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Tumor/Cancer Marker Testing Products, Fecal Occult Testing Products, and Others. The Glucose Monitoring Products segment is expected to dominate the largest market revenue share of 40.96% in 2026, driven by the growing Asia-Pacific burden of diabetes, rising demand for home-based self-monitoring, and continuous technological advancements in blood glucose meters and connected digital health platforms.

• By Platform

On the basis of Platform, the Asia-Pacific Point-Of-Care-Testing (POCT) Market is segmented Lateral Flow Assays/Immunochromatography Tests, Immunoassays, Dipsticks, Molecular Diagnostics, Clinical Chemistry Assays, Microfluidics, Hematology, Others. The Lateral Flow Assays/Immunochromatography Tests is expected to dominate in 2026, supported by their widespread adoption in infectious disease screening, ease of use, rapid result turnaround, low cost, and extensive use during outbreaks such as COVID-19, influenza, malaria, and dengue. Their suitability for decentralized and remote healthcare settings further strengthens segment growth.

• By Application

On the basis of Application, the Asia-Pacific Point-Of-Care-Testing (POCT) Market is segmented into Blood Glucose, Infectious Diseases, Vital Sign Monitoring, Cardiac Monitoring, Coagulation, Haematology, Non- Invasive SpO2 Monitoring, Blood Transfusion, Non- Invasive PCO2 Monitoring, Whole Blood Analysis, Others. The Blood Glucose is expected to dominate with the largest market revenue share in 2026, driven by rising diabetes prevalence, increasing patient preference for portable monitoring devices, and the availability of highly accurate, user-friendly glucometers and continuous glucose monitoring (CGM) technologies that support real-time diabetes management.

• By Prescription Mode

On the basis of Prescription Mode, the Asia-Pacific Point-Of-Care-Testing (POCT) Market is segmented into OTC Testing, Prescription-Based Testing. The OTC Testing segment accounted for the largest market revenue share in 2026, by the increasing consumer preference for self-testing solutions, growing availability of rapid diagnostic kits, and the rising focus on preventive healthcare. OTC POCT devices enable individuals to monitor health parameters such as glucose levels, pregnancy, fertility, infectious diseases, and cardiovascular indicators without clinical supervision.

• By End User

On the basis of End User, the Asia-Pacific Point-Of-Care-Testing (POCT) Market is segmented into Hospitals, Home Care, Clinics, Laboratories, Diagnostic Centers, Pathology Labs, Ambulatory Surgery Centers, Elderly Care Centers, Others. The Hospitals segment accounted for the largest market revenue share in 2026, driven by the high demand for rapid diagnostic testing to support emergency care, critical care, and routine clinical assessments. POCT devices—such as blood glucose meters, cardiac marker analyzers, infectious disease rapid tests, coagulation monitors, and blood gas analyzers—are increasingly utilized in hospital settings to enable faster clinical decision-making, reduce patient turnaround time, and improve workflow efficiency.

• By Distribution Channel

On the basis of Distribution Channel, the Asia-Pacific Point-Of-Care-Testing (POCT) Market is segmented into Direct Tender, Retail Sales, Online Sales, Others. The Direct Tender segment accounted for the largest market revenue share in 2026, driven by the high-volume procurement of POCT devices by hospitals, diagnostic laboratories, and public health agencies. Large-scale tenders ensure consistent supply of essential diagnostic tools—such as glucose monitors, rapid infectious disease test kits, cardiac biomarker analyzers, and coagulation testing devices—required for routine testing and emergency care.

Asia-Pacific Point-Of-Care-Testing (POCT) Market Regional Analysis

• Asia-Pacific dominated the Asia-Pacific Point-Of-Care-Testing (POCT) Market with the largest revenue share of over 21.28% in 2025, driven by the region’s rapidly expanding healthcare infrastructure, rising burden of chronic diseases, and increasing adoption of decentralized diagnostic technologies. Countries such as U.S., Canada and Mexico are witnessing strong demand for rapid diagnostic kits for diabetes, infectious diseases, cardiovascular conditions, and home-based monitoring.
• Growing investment in digital health, telemedicine expansion, and government initiatives supporting early diagnosis further accelerate POCT deployment. Additionally, the large geriatric population and rising consumer preference for affordable, quick medical testing are reinforcing market growth across the region.

Japan Asia-Pacific Point-Of-Care-Testing (POCT) Market Insight

The Japan POCT market is gaining strong momentum due to the country’s advanced healthcare systems, high technological adoption, and focus on precision diagnostics. Japan’s aging population has significantly increased demand for rapid testing solutions for chronic and lifestyle-related diseases, including diabetes, kidney diseases, and cardiovascular disorders. The country’s strong emphasis on preventive healthcare, coupled with innovations in miniaturized diagnostic platforms, supports market expansion. Additionally, Japan’s leadership in biotechnology, microfluidics, and sensor technology is fostering the development of highly accurate POCT devices tailored for both clinical and home-care settings.

China Asia-Pacific Point-Of-Care-Testing (POCT) Market Insight

China accounted for the largest share of the Asia-Pacific POCT market in 2025, driven by its fast-growing healthcare ecosystem, rising incidence of infectious and chronic diseases, and increasing reliance on portable diagnostics in primary care and rural healthcare settings. The government’s strong push toward improving healthcare accessibility and self-testing adoption has amplified demand for rapid antigen tests, glucose monitoring kits, and pregnancy/fertility tests. China’s cost-effective manufacturing capabilities and expansion of domestic diagnostic companies have also accelerated production and export of POCT devices. Growing adoption of digital connectivity in diagnostics and improved reimbursement pathways further support sustained market growth.

Asia-Pacific Point-Of-Care-Testing (POCT) Market Share

The Point-Of-Care-Testing (POCT) industry is primarily led by well-established companies, including:

• Abbott Point of Care Inc. (U.S.)
• Sinocare Inc. (China)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Danaher Corporation (U.S.)
• Hologic, Inc. (U.S.)
• bioMérieux SA (France)
• Siemens Healthineers AG (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• BD Veritor (Becton, Dickinson and Company) (U.S.)
• QuidelOrtho Corporation (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Werfen (Spain)
• Sekisui Diagnostics (Japan)
• Trividia Health, Inc. (U.S.)
• Nova Biomedical Corporation (U.S.)
• Meridian Bioscience, Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Shenzhen New Industry Biomedical Engineering Co., Ltd. (China)
• Sysmex Corporation (Japan)
• Wondfo (Guangzhou Wondfo Biotech Co., Ltd.) (China)
• QIAGEN N.V. (Germany)
• Abaxis, Inc. (U.S.)
• Autobio Diagnostics Co., Ltd. (China)
• Getein Biotech, Inc. (China)
• Chembio Diagnostics, Inc. (U.S.)
• EKF Diagnostics Holdings plc (U.K.)
• Trinity Biotech plc (Ireland)
• PTS Diagnostics (U.S.)
• QuantuMDx Group Ltd. (U.K.)
• Binx Health (U.S.)
• Xiamen Boson Biotech Co., Ltd. (China)
• Accubiotech Co., Ltd. (China)
• Sienco, Inc. (U.S.)
• LamdaGen Corporation (U.S.)

Latest Developments in Asia-Pacific Point-Of-Care-Testing (POCT) Market

• In May 2020, Abbott's ID NOW COVID-19 test provides rapid, reliable results in minutes, aiding in timely diagnosis and reducing infection risk. Studies show strong performance in urgent care settings, with ≥94.7% sensitivity and ≥98.6% specificity. Despite challenges from an NYU study, real-world data supports its effectiveness. Authorized under FDA's emergency use authorization, the test plays a crucial role in COVID-19 detection.
• In September 2025, Sinocare’s subsidiary Dongguan E-Test Technology has received FDA 510(k) clearance for its Multi-Series Smart Blood Pressure Monitors, highlighting their accuracy, safety, and wireless capabilities. The devices offer medical-grade monitoring, Bluetooth connectivity, and intelligent alerts, strengthening Sinocare’s Asia-Pacific expansion strategy and enhancing its chronic disease management ecosystem across international markets, including the U.S. and Europe.
• In January 2025, Danaher Corporation has formed an investment partnership with Innovaccer Inc., a healthcare AI company. This collaboration aims to accelerate the adoption of precision diagnostics and value-based care by providing healthcare providers with unified patient data and advanced analytics, improving patient outcomes through personalized, timely interventions.
• In November 2023, Binx Health has partnered with Fisher Healthcare to expand distribution of the FDA-cleared binx io, a molecular point-of-care platform for detecting chlamydia and gonorrhea. This system provides lab-quality results in about 30 minutes, improving timely diagnoses and enabling clinicians to test and treat patients during a single visit, enhancing care access.

SKU-3226